In a new research note, Jefferies makes the case that earnings could give a lift to the sagging market, and with low expectations, the lift could be solid.
The short interest data have been released for the December 15 settlement date, and for most of the selected pharmaceutical stocks short interest was up.
24/7 Wall St. screened the Jefferies Franchise Picks list for the top-yielding stocks and found four with outstanding growth potential.
The November 30 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest was up.
Brokerage firm Jefferies has released its top pharmaceutical picks for the coming year and what to expect.
The Franchise Picks list makes sense for solid growth investors looking for total return. Many of the stocks pay good dividends and have upside price potential.
Tuesday's top analyst upgrades, downgrades and initiations include AbbVie, CDW, CSC, Eli Lilly, Ericsson, Gold Fields, JD.com, Nokia and Rackspace.
Buying high-yielding blue chips for 2016 makes good sense. The Federal Reserve interest rate increases over the next two years are expected to remain very small and very measured.
You may want to avoid these stocks over the next few months.
Jefferies has updated the thesis behind its "Top 5 for 2015" pharmaceutical stock picks
The short interest data have been released for the October 30 settlement date, and for most of the selected pharmaceutical stocks, short interest was down.
Buying stocks such as these, with solid growth potential and paying dividends higher than the 10-year Treasury debt, makes good sense now.
Tuesday's top analyst upgrades, downgrades and initiations include AbbVie, Apple, Autodesk, JD.com, CyberArk, Dean Foods and Walt Disney.
AbbVie reported better-than-expected third-quarter financial results before the markets opened on Friday.
Chris Lange AbbVie is expected to report its third-quarter financial results before the markets open on Friday.
Chris Lange 
